Cellectis S.A. logo
Cellectis S.A. CLLS
$ 4.16 -6.94%

Annual report 2024
added 01-17-2026

report update icon

Cellectis S.A. Financial Statements 2011-2026 | CLLS

Annual Financial Statements Cellectis S.A.

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

- - - 203 M 914 M 715 M 818 M 1.16 B 619 M 764 M - - - -

Shares

- - - 44.8 M 42.5 M 45.8 M 45.8 M 37.3 M 35.3 M 34.1 M - - - -

Historical Prices

1.27 3.24 2 4.53 21.5 15.6 17.9 31.2 22.3 23.8 - - - -

Net Income

- - - -125 M -81.1 M -115 M -88.3 M -104 M -64.1 M -22.5 M 24.3 K -84.3 M -29.5 M -30.9 M

Revenue

41.5 M 755 K 19.2 M 30.3 M 51.1 M 15.2 M 12.7 M 25.2 M 53.8 M 55 M 26.3 M 22.8 M 27.8 M 20.7 M

Cost of Revenue

- - - 31.4 M 36.3 M 11.4 M 2.74 M 2.62 M - - - - - -

Gross Profit

- - - - 37.7 M 11.6 M 21.4 M 33.7 M 53.8 M 52.3 M 22.6 M 22 M 25.8 M 17.5 M

Operating Income

- - - -131 M -85.4 M -124 M -105 M -92.6 M -67.3 M -31 M -6.97 M - - -

Interest Expense

- - 371 K 368 K 73 K 3 K 39 K - - 1 K - - - -

EBITDA

- - - -131 M -85.4 M -124 M -105 M -92.6 M 2.46 M -28.6 M -4.71 M 776 K -26.1 M -24.5 M

Operating Expenses

109 M 106 M 115 M 142 M 102 M 147 M 127 M 126 M 105 M 82.9 M 29 M 67.1 M 51.9 M 42.8 M

General and Administrative Expenses

- - - 37.9 M 44.2 M -43 M -47.2 M -44.8 M -41.4 M 29.8 M 15.9 M 30.5 M - -

All numbers in USD currency

Quarterly Income Statement Cellectis S.A.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - - - 45.5 M - - - 42.5 M - - - 42.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

- - - - - - -41.6 M - - - -35.9 M - - - -36.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

- - - - - - 11.2 M - - - 2.9 M - - - 1.15 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

- - - - - - 11.8 M - - - 5.83 M - - - 815 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

- - - - - - -37.5 M - - - -33 M - - - -35.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

- - - - - - -37.5 M - - - -33 M - - - -35.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

- - - - - - 52.1 M - - - 37.6 M - - - 38.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

- - - - - - 9.34 M - - - 9.07 M - - - 11.8 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Cellectis S.A. CLLS
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Cellectis S.A. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 2.45 -1.61 % $ 138 M chinaChina
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Biogen Biogen
BIIB
$ 172.45 0.5 % $ 25.1 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.97 0.81 % $ 5.29 M chinaChina
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.65 2.82 % $ 8.78 B australiaAustralia
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
BioNTech SE BioNTech SE
BNTX
$ 117.57 1.37 % $ 27.2 B germanyGermany
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.79 -1.64 % $ 4.54 M usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 2.94 -5.16 % $ 908 M israelIsrael
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.13 -5.23 % $ 799 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 233.71 -0.71 % $ 5 B danmarkDanmark
Burford Capital Limited Burford Capital Limited
BUR
$ 9.81 0.56 % $ 1.57 B britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 67.35 0.45 % $ 9.01 B usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.06 -1.67 % $ 184 M israelIsrael
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.43 -0.78 % $ 9.64 B israelIsrael
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 25.89 -0.14 % $ 1.25 B usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 2.28 10.68 % $ 215 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 13.48 0.67 % $ 4.17 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 26.53 2.35 % $ 1.71 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.74 1.48 % $ 17.2 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
$ 94.2 1.34 % $ 96.9 B britainBritain
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA